enGene Therapeutics Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
enGene Therapeutics disclosed interim data from its pivotal LEGEND Phase 2 cohort (N=125, BCG-unresponsive high-risk NMIBC with CIS) showing 54% complete response (CR) at any time, with low dose interruption (2.4%) and discontinuation (2.4%) rates. The company holds $285M cash and expects to file a BLA in 2H 2026, with potential FDA approval and platform designation in 2027. A surfactant bladder rinse formulation is in development with preclinical data suggesting 9-10x improved IL-12 expression and efficacy.
Why this rating
54% CR interim efficacy is competitive with approved agents; $285M runway covers BLA path. Relative to $154M market cap, clinical validation + cash adequacy substantially reduces execution risk, though regulatory and commercial success remain uncertain.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.